Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL202 vs docetaxel in EGFR-mutated non-squamous NSCLC
ChiCTR2600120457Phase 3Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of YL202 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai East Hospital. Primary endpoints: Progression-free survival and Overall survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
YL202
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600120457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120457.